Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa
Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.
You may also be interested in...
The biotech announces another set of positive anti-seizure results for its marijuana-derived product.
The table records clinical and regulatory developments using data from BioMedTracker. It lists all drugs for which an event was recorded from April 15 to April 21, 2016, divided by event type.
Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.